Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group.

Baruchel S, Pappo A, Krailo M, Baker KS, Wu B, Villaluna D, Lee-Scott M, Adamson PC, Blaney SM.

Eur J Cancer. 2012 Mar;48(4):579-85. doi: 10.1016/j.ejca.2011.09.027. Epub 2011 Nov 14.

PMID:
22088484
[PubMed - indexed for MEDLINE]
2.

Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.

[No authors listed]

Drugs R D. 2006;7(5):317-28. Review.

PMID:
16922593
[PubMed - indexed for MEDLINE]
3.

Trabectedin for the treatment of advanced metastatic soft tissue sarcoma.

Simpson EL, Rafia R, Stevenson MD, Papaioannou D.

Health Technol Assess. 2010 May;14 Suppl 1:63-7. doi: 10.3310/hta14Suppl1/09. Review.

PMID:
20507805
[PubMed - indexed for MEDLINE]
Free Article
4.

Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.

Forouzesh B, Hidalgo M, Chu Q, Mita A, Mita M, Schwartz G, Jimeno J, Gómez J, Alfaro V, Lebedinsky C, Zintl P, Rowinsky EK.

Clin Cancer Res. 2009 May 15;15(10):3591-9. doi: 10.1158/1078-0432.CCR-08-2889. Epub 2009 May 5.

PMID:
19417019
[PubMed - indexed for MEDLINE]
Free Article
5.

Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.

Blaney SM, Needle MN, Gillespie A, Sato JK, Reaman GH, Berg SL, Adamson PC, Krailo MD, Bleyer WA, Poplack DG, Balis FM.

Clin Cancer Res. 1998 Feb;4(2):357-60.

PMID:
9516923
[PubMed - indexed for MEDLINE]
Free Article
6.

Trabectedin for the management of soft-tissue sarcoma.

Boudou L, Baconnier M, Blay JY, Lombard-Bohas C, Cassier PA.

Expert Rev Anticancer Ther. 2009 Jun;9(6):727-37. doi: 10.1586/era.09.28. Review.

PMID:
19496709
[PubMed - indexed for MEDLINE]
7.

Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.

Paz-Ares L, López-Pousa A, Poveda A, Balañá C, Ciruelos E, Bellmunt J, del Muro JG, Provencio M, Casado A, Rivera-Herrero F, Izquierdo MA, Nieto A, Tanović A, Cortes-Funes H, Buesa JM.

Invest New Drugs. 2012 Apr;30(2):729-40. doi: 10.1007/s10637-010-9561-9. Epub 2010 Oct 20.

PMID:
20960029
[PubMed - indexed for MEDLINE]
8.

A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.

Le Cesne A, Cresta S, Maki RG, Blay JY, Verweij J, Poveda A, Casali PG, Balaña C, Schöffski P, Grosso F, Lardelli P, Nieto A, Alfaro V, Demetri GD.

Eur J Cancer. 2012 Nov;48(16):3036-44. doi: 10.1016/j.ejca.2012.05.012. Epub 2012 Jun 29.

PMID:
22749255
[PubMed - indexed for MEDLINE]
9.

A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors.

Chuk MK, Aikin A, Whitcomb T, Widemann BC, Zannikos P, Bayever E, Balis FM, Fox E.

Pediatr Blood Cancer. 2012 Nov;59(5):865-9. doi: 10.1002/pbc.24201. Epub 2012 Jul 27.

PMID:
22847981
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Trabectedin: new drug. Soft-tissue sarcomas: too many adverse effects.

[No authors listed]

Prescrire Int. 2009 Aug;18(102):161. No abstract available.

PMID:
19743575
[PubMed - indexed for MEDLINE]
11.

Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma.

Schöffski P, Dumez H, Wolter P, Stefan C, Wozniak A, Jimeno J, Van Oosterom AT.

Expert Opin Pharmacother. 2008 Jun;9(9):1609-18. doi: 10.1517/14656566.9.9.1609 . Review.

PMID:
18518789
[PubMed - indexed for MEDLINE]
12.

Trabectedin.

Dubois EA, Cohen AF.

Br J Clin Pharmacol. 2009 Sep;68(3):320-1. doi: 10.1111/j.1365-2125.2009.03490.x. No abstract available.

PMID:
19740389
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.

Carter NJ, Keam SJ.

Drugs. 2007;67(15):2257-76. Review.

PMID:
17927287
[PubMed - indexed for MEDLINE]
14.

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.

Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, Lorigan P, Rodenhuis S, Ray-Coquard I, Bonvalot S, Collin F, Jimeno J, Di Paola E, Van Glabbeke M, Nielsen OS.

J Clin Oncol. 2005 Jan 20;23(3):576-84. Erratum in: J Clin Oncol. 2005 Aug 1;23(22):5276.

PMID:
15659504
[PubMed - indexed for MEDLINE]
Free Article
15.

Therapy-related acute myeloid leukemia following treatment with trabectedin for Ewing's sarcoma.

Liu SV, Zneimer S, Tahbaz A, Douer D.

Acta Haematol. 2011;126(2):76-8. doi: 10.1159/000324936. Epub 2011 Apr 18. No abstract available.

PMID:
21502754
[PubMed - indexed for MEDLINE]
16.

A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study.

Lau L, Supko JG, Blaney S, Hershon L, Seibel N, Krailo M, Qu W, Malkin D, Jimeno J, Bernstein M, Baruchel S.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):672-7.

PMID:
15701855
[PubMed - indexed for MEDLINE]
Free Article
17.

Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: good tolerance profile and efficacy in rhabdomyosarcoma--a report from the Société Française des Cancers et leucémies de l'Enfant et de l'adolescent (SFCE).

Minard-Colin V, Ichante JL, Nguyen L, Paci A, Orbach D, Bergeron C, Defachelles AS, André N, Corradini N, Schmitt C, Tabone MD, Blouin P, Sirvent N, Goma G, Geoerger B, Oberlin O.

Eur J Cancer. 2012 Oct;48(15):2409-16. doi: 10.1016/j.ejca.2012.04.012. Epub 2012 May 25.

PMID:
22633624
[PubMed - indexed for MEDLINE]
18.

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, Quigley MT, Merriam P, Canniff J, Goss G, Matulonis U, Maki RG, Lopez T, Puchalski TA, Sancho MA, Gomez J, Guzman C, Jimeno J, Demetri GD.

J Clin Oncol. 2004 Apr 15;22(8):1480-90.

PMID:
15084621
[PubMed - indexed for MEDLINE]
Free Article
19.

Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre.

Roylance R, Seddon B, McTiernan A, Sykes K, Daniels S, Whelan J.

Clin Oncol (R Coll Radiol). 2007 Oct;19(8):572-6. Epub 2007 Jul 10.

PMID:
17624747
[PubMed - indexed for MEDLINE]
20.

Trabectedin in advanced soft tissue sarcoma: case series.

Demirci U, Buyukberber S, Yetisyigit T, Dizdar O, Benekli M, Alkis N, Coskun U; Anatolian Society of Medical Oncology (ASMO).

J BUON. 2012 Jul-Sep;17(3):591-2.

PMID:
23033305
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk